Company intelligence / Profile preview

Sollis Therapeutics

Columbus, Ohio, United States

Ownership: Private
Development stage: Other

Overview

A Phase 3 randomized, double-blind, sham-controlled study evaluating STX-015 showed safety and efficacy in treating low back and leg pain from sciatica; however, this trial was terminated according to clinical trial records. Another long-term safety follow-up study was completed successfully.

Therapeutic areas: OncologyPsychiatryNeurology
Modalities: novel interventional non-steroid, non-opioid analgesic therapeuticsclonidine micropellets
Industry: Biotech

Drug pipeline

1 asset

STX-015

Discontinued

Beyond the preview

Go deeper on Sollis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sollis Therapeutics.

Explore the full profile